Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026

Evidence / Men's Sexual Health

CoverageMen's Sexual Health

Is erectile dysfunction a marker of future cardiovascular disease?

Updated Sep 2026·12 studies analyzed·2 core studies·Applies to: hypogonadal men

Bottom line

Erectile dysfunction often precedes symptomatic cardiovascular disease and shares endothelial dysfunction pathways with atherosclerosis. Men presenting with ED warrant cardiovascular risk assessment and conventional prevention strategies independent of PDE5 therapy decisions.[1–6]

Evidence confidence

Evidence Confidence

High
LimitedModerateHigh

Multiple high-quality studies directly address this question, with generally consistent findings.

Key uncertainty. ED improves risk stratification but is not a standalone diagnostic test for coronary disease.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Also asked

ED predicts heart disease▼

Erectile dysfunction often precedes symptomatic cardiovascular disease and shares endothelial dysfunction pathways with atherosclerosis. Men presenting with ED warrant cardiovascular risk assessment and conventional prevention strategies independent of PDE5 therapy decisions.

Erectile dysfunction cardiovascular risk▼

Erectile dysfunction often precedes symptomatic cardiovascular disease and shares endothelial dysfunction pathways with atherosclerosis. Men presenting with ED warrant cardiovascular risk assessment and conventional prevention strategies independent of PDE5 therapy decisions.

ED as sentinel for atherosclerosis▼

Erectile dysfunction often precedes symptomatic cardiovascular disease and shares endothelial dysfunction pathways with atherosclerosis. Men presenting with ED warrant cardiovascular risk assessment and conventional prevention strategies independent of PDE5 therapy decisions.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 3 relevant studies.

Overall finding

3 studies address erectile function, with weighted findings showing a positive association. 2 studies address sexual desire, with weighted findings showing a positive association. 2 studies address sexual activity, with weighted findings showing a positive association. 2 randomized or systematic-review reports and 0 observational studies address treatment. Treat new erectile dysfunction as a potential sentinel for vascular disease: screen lipids, blood pressure, glucose, and lifestyle factors even when the patient requests only ED therapy.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Positive link

Erectile function

high · 3 studies

3 studies address erectile function, with weighted findings showing a positive association.

Mixed measurement

Positive link

Sexual desire

high · 2 studies

2 studies address sexual desire, with weighted findings showing a positive association. This is a patient-reported / subjective outcome.

Patient-reported

Positive link

Sexual activity

high · 2 studies

2 studies address sexual activity, with weighted findings showing a positive association. This is a patient-reported / subjective outcome.

Patient-reported

Magnitude / clinical importance

Validated effect estimates in the analyzed set include mean difference=2.31; or 100. Statistical significance is not the same as clinical importance.

Interpret magnitude in absolute terms for the patient in front of you, not from relative estimates alone.

Agreement across studies

Findings are mostly consistent with minor variation after weighting by design, quality, and directness.

Supports main conclusion: 2 · Neutral / mixed: 1 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

Oral sildenafil is an effective, well-tolerated treatment for men with erectile dysfunction.

Who this applies to

Most studies included hypogonadal men.

What remains uncertain

  • ED improves risk stratification but is not a standalone diagnostic test for coronary disease.
  • ED improves risk stratification but is not a standalone diagnostic test for coronary disease.

Clinical takeaway

Treat new erectile dysfunction as a potential sentinel for vascular disease: screen lipids, blood pressure, glucose, and lifestyle factors even when the patient requests only ED therapy.

Positive link

Erectile function?

A positive association

high[28434676 · 27355400 · 9580646]

Positive link

Sexual desire?

A positive association

high[28434676 · 27355400]

Positive link

Sexual activity?

A positive association

high[28434676 · 27355400]

2 randomized or systematic-review reports and 0 observational studies address treatment. Weighted treatment findings show a positive association.

2 RCT / systematic review · 0 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

10 supporting studies add context beyond the core evidence base.

Regimen & duration

Differences in hormone type, dose, duration, and patient population affect how results should be interpreted.

Long-term uncertainty

Evidence beyond long follow-up windows and in certain subgroups remains less complete.

3 analyzed studies

Strongest evidence

European urology2017

Landmark studyPMID 28434676

Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.

TTh significantly improves erectile function and other sexual parameters as measured by IIEF in hypogonadal men. These results argue that sexual dysfunction should be considered a hallmark manifestation of T deficiency, since those symptoms can be significantly improved with normalization of serum T.

Systematic review
Evidence
Relevance

Supporting literature

Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels.

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial.

+7 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Men's Sexual Health.

Go deeper on Men's Sexual Health

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.